Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour which arises from thyroid C-lls. Surgery is the main treatment when the disease is confined to the neck (Wahl and Roher, 1988) . Extenal irradiation may be indicated in patients with a dectable cakcitonin level after an apparently complete surgical procedure (Schlumberger et al., 1991) . Chemotherapy plays no role in the early management. This disease usually follows an indolent course even at the stage of diant spread, and patients with lung or liver metastases may survive years without systemic treatment. In a minority of these metas patients, chemotherapy may be indicated for rapidly progrssng distant metaa.
Chemotherapy trials have been imited by the scarcity of these tumours. Response rates were low with doxorubicin (Gottlieb and Hill 1975; Husain et al., 1978; Shimaoka et al., 1985; Hosidn and Harmer, 1987; Droz et al., 1990) and cisplatin (Hosin and Harmer, 1987; Droz et al., 1990) , given either as single agents or in combination (Shimaoka et al., 1985; Sridhar et al., 1985; Williams et al., 1986; Droz et al., 1990) . Furthermore, toxcities were siant. A recent trial (M Schlumberger, unpublished data) with etoposide given as a single agent did not confirm a previous report (Hoskin and Harmer, 1987) , as no tumour response was observed among 16 evaluable patients. Interferon a2a (Schlumberger et al., 1991) and somatostatin analogues (Mahler et al., 1990; Modigii et al., 1992) did not produce any tumour response. Therefore, there is a clear need for investigation of other agents in the treatment of this diseas.
In the present triaL three drugs which have been shown to be active in other neuroendocrine tumours (Kessinger et al., 1983) were givn, by alternating a combination of 5-fluorouracil and streptozocin with a combination of 5-fluorouracil and dacarbazie. This was further encouraged by the anecdotal report of the effiacy of 5-fluorouracil and daarbazine in two MTC patients (Pursson, 1988 Patients' eligibility requirements included leucocyte count greater than 4000 i1-l and platelet count greater than 150000pl-', a serum creatinine of 120pmolI-I or less, a total bilirubin of kss than or equal to 342 pmol 1-I and no chemotherapy during the preding 3 months. Informed consent was obtained from all patients.
Treatiw
Before therapy, and also at the time of each evaluation, a medical history was taken, and the patient underwent physical examination and tumour measurements. Laboratory analysis kucocyte count, platelet count, haemoglobin, a blood chemistry pane, ECG and assays of serm CT and CEA. Appropriate images were obtained of any indicator lesions. Therapy was ni in the hospital. During the first course, dacarbazine was given at 200mgm2 and 5-FU at 400mgm2, both by intravenous injection daily for 5 days. Three weeks later, steptozocin was given at 500mg m-2 and 5-FU at 400mg m2, both by intravenous injection daily for 5 days. At 6 weeks, this cyce was repeated. tumour responses were observed after one, seven and three cycles of chemotherapy, and lasted 11, 9 and 8 months respecuively. In two patients (cases 8 and 14) all tumour sites responded, whereas in patient 7 a partial response was observed in skin and liver and a stabilization in lung metastases. Calcitonin level dereased by 52%, 38% and 15% respecively, and CEA level decreased by 91°% in patient 8, was stable in patient 14 and increased by 64% in patient 7. Eleven patients had a stable disease for 4-29 months (mean 12.8 months): the performance status improved in seven of these patients, remained unchanged in three and worsened in patient 20. Nine of these 11 patients with a stable disease had previously been treated with other drug regimens and none of them responded. Six patients had progressive disease.
Nausea and vomiting were limited by antiemetic drugs and digestive toxicity was observed in four patients (grade 2 in two and grade 3 in two patients). One patient had a stomatitis (grade 2). Alopecia (grade 2) was observed in two patients, renal toxicity (grade 2 and 3) in two, cardiac toxicity (grade 3) in two and hepatic toxicity (grade 2) in one patient. No myelotoxicity or infection was observed.
The indication for systemic cytotoxic chemotherapy treatment in MTC patients was rapidly progressive disease. In such patients, the actual response rate is unknown. Doxorubicin has been the most frequently reported agent with a response rate probably not higher than 15-20%, all responses being partial and transient and with high toxicities.
Combination of doxorubicn with other drugs such as cisplatin (Shimaoka et al., 1985; Sridhar et al., 1985; Williams et al., 1986; Droz et al., 1990 ), or streptozocin (Kelson et al., 1982 did not increase the response rate.
Responses to this combined regimen compared favourably with other therapeutic trials in patients with metastatic meduflary thyroid carcinoma in terms of both response rate and of toxicity (Wu et al., 1994) . In fact, three patients achieved a partial response and 11 other patients a stabilization, with an improvement in performance status in seven, for long periods of time. Of note, this regimen may be effective with an acceptable toxicity even in patients who had already been treated with other drug regimens. Response to therapy may be rapid or may occur after several courses of chemotherapy, in accordance with the slow growth rate of most of these tumours. Therefore, this study demonstrates clearly that, at least in some patients, this combination is effective, and favours new therapeutic trials using other combination regimens with these drugs.
